Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Cowin Biotech CoSHSE:688426 +3.28%63 PB Ratio is 1.30 as of Jul. 27, 2026, which is 30% below its 10-year median of 1.85. GuruFocus rates SHSE:688426 with a GF Score™ of 63/100 and a GF Value™ of ¥29.26 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,230 Biotechnology companies, Jiangsu Cowin Biotech Co ranks better than 74.39% on this metric.
Jiangsu Cowin Biotech Co Ltd stock PB Ratio (=1.26) is close to 2-year low of 1.14.
The historical rank and industry rank for Jiangsu Cowin Biotech Co's PB Ratio or its related term are showing as below:
SHSE:688426'
s PB Ratio Range Over the Past 10 Years
Min: 1.08 Med: 1.85 Max: 6.48
Current: 1.3
During the past 8 years, Jiangsu Cowin Biotech Co's highest PB Ratio was 6.48. The lowest was 1.08. And the median was 1.85.
SHSE:688426's PB Ratio is ranked better than 74.39% of 1230
companies
in the Biotechnology industry
Industry Median: 2.785
vs SHSE:688426: 1.30
During the past 12 months, Jiangsu Cowin Biotech Co's average Book Value Per Share Growth Rate was -7.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 20.20% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Jiangsu Cowin Biotech Co was 171.90% per year. The lowest was -8.90% per year. And the median was 44.30% per year.
Back to Basics: PB Ratio
Jiangsu Cowin Biotech Co (SHSE:688426) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688426 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Jiangsu Cowin Biotech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Cowin Biotech Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Cowin Biotech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Cowin Biotech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jiangsu Cowin Biotech Co (SHSE:688426) has a PB Ratio of 1.30 as of Jul. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangsu Cowin Biotech Co and its competitors. This is 30% below median its historical median of 1.85. Over the past decade, Jiangsu Cowin Biotech Co's PB Ratio has ranged from 1.08 to 6.48. According to the industry distribution chart, Jiangsu Cowin Biotech Co ranks #315 out of 1230 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Jiangsu Cowin Biotech Co's PB Ratio too high?
Jiangsu Cowin Biotech Co's current PB Ratio of 1.30 is 30% below median its 10-year median of 1.85. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 6.48. The Biotechnology industry median PB Ratio is 2.79. Jiangsu Cowin Biotech Co's value of 1.30 is 53.3% below this industry median. Based on the distribution chart, Jiangsu Cowin Biotech Co ranks #315 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jiangsu Cowin Biotech Co has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Cowin Biotech Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Cowin Biotech Co ranks #315 out of 1230 companies for PB Ratio. This puts Jiangsu Cowin Biotech Co in the upper half of its industry. The industry median PB Ratio is 2.79. Jiangsu Cowin Biotech Co's value of 1.30 is 53.3% below this benchmark. Historically, Jiangsu Cowin Biotech Co's own PB Ratio has ranged from 1.08 to 6.48 over the past decade. While the company's 10-year median is 1.85 vs. the industry median of 2.79, Jiangsu Cowin Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Cowin Biotech Co's current PB Ratio of 1.30 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangsu Cowin Biotech Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Cowin Biotech Co's current PB Ratio is 1.30, which is 30% below median its own 10-year median of 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Cowin Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co (SHSE:688426) is currently considered Possible Value Trap. The stock's GF Value™ is ¥29.26, compared to a current price of ¥15.44 — trading 47.2% below its estimated fair value. The current PB Ratio is 1.30, which is 30% below median its 10-year median of 1.85 and 53.3% below the Biotechnology industry median of 2.79. Jiangsu Cowin Biotech Co's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jiangsu Cowin Biotech Co (SHSE:688426), the current PB Ratio is 1.30 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Cowin Biotech Co (SHSE:688426) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co stock appears to be undervalued.
The current stock price of ¥15.44 is trading 47.2% below its estimated GF Value™ of ¥29.26.
GuruFocus considers Jiangsu Cowin Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688426:
PB Ratio: 1.30 (30% below median its 10-year median of 1.85)
GF Value™: ¥29.26 vs. price of ¥15.44 (47.2% below fair value)
Industry Position: 53.3% below the Biotechnology median (#315 of 1230)
No single metric tells the full story. See the SHSE:688426 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
63GF Score
Get the complete analysis for SHSE:688426
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688426 has been successfully added to your 
